Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.3% – Time to Sell?

by · The Markets Daily

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report)’s share price fell 5.3% during trading on Monday . The stock traded as low as $0.31 and last traded at $0.32. 28,828,476 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 30,399,371 shares. The stock had previously closed at $0.34.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday. They set a “hold” rating for the company.

Check Out Our Latest Stock Report on Tonix Pharmaceuticals

Tonix Pharmaceuticals Price Performance

The stock has a 50 day moving average of $0.23 and a two-hundred day moving average of $0.37. The stock has a market cap of $61.64 million, a PE ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Further Reading